A randomized, controlled study of sulodexide therapy for the treatment of diabetic nephropathy

Nephrology Dialysis Transplantation

Volumn 12, Issue 11, 1997, Pages 2295-2300

  Dedov, I ^a   Shestakova, M ^a   Vorontzov, A ^a   Palazzini, E ^b  

^a N N BLOKHIN NATIONAL MEDICAL RESEARCH CENTER OF ONCOLOGY   (Russian Federation)

^b Alfa Wassermann SpA   (Italy)

Author keywords

Albuminuria; Diabetes mellitus; Diabetic nephropathy; Glycosaminoglycans

Indexed keywords

ALBUMIN; CHOLESTEROL; GLYCOSAMINOGLYCAN; SULODEXIDE; TRIACYLGLYCEROL; UNCLASSIFIED DRUG; VESSEL DUE F;

ARTICLE; BLOOD CHEMISTRY; BLOOD CLOTTING; BLOOD PRESSURE; CHOLESTEROL BLOOD LEVEL; CLINICAL ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIABETIC NEPHROPATHY; FEMALE; FOLLOW UP; HUMAN; HYPERLIPIDEMIA; INSULIN DEPENDENT DIABETES MELLITUS; INTRAMUSCULAR DRUG ADMINISTRATION; MALE; MICROALBUMINURIA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEINURIA; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL; URINALYSIS; URINARY EXCRETION;

ADULT; ALBUMINURIA; DIABETIC NEPHROPATHIES; FEMALE; GLYCOSAMINOGLYCANS; HUMANS; MALE;

EID: 0030719936     PISSN: 09310509     EISSN: None     Source Type: Journal    
DOI: 10.1093/ndt/12.11.2295     Document Type: Article

References (29)

1. Borch-Johnsen K, Kreiner S. Proteinuria value as a predictor of cardiovascular mortality in insulin dependent diabetes mellitus. Br Med J 1987; 294: 1651-1654
2. Gilbert RE, Cooper ME, McNally PG, O'Brien RC, Taft J. Jerums G. Microalbuminuria: prognostic and therapeutic implications in diabetes mellitus. Diab Med 1994; 11: 636-645
3. Trevisan R, Viberti GC. Genetic predisposition and diabetic nephropathy. Diab Nutr Metab 1995; 8: 159-165
4. Deckert T. Glycemic control and complications. In: Albertik GMM, Krall LP (eds) The Diabetes Annual 4. Elsevier Science Publishers BV, 1988; 496-518
5. Osterby R. Glomerular structural changes in type 1 (insulin-dependent) diabetes mellitus: causes, consequences, and prevention. Diabetologia 1992; 35: 803-812
6. Gambaro G, Cavazzana AO, Luzi P et al. Glycosaminoglycans prevent morphological renal alterations and albuminuria in diabetic rats. Kidney Int 1992; 42: 285-291
7. Kofoed-Enevoldsen A. Heparan sulphate in the pathogenesis of diabetic nephropathy. Diab/Metab Rev 1995; 11: 137-160
8. Gambaro G, Baggio B. Role of glycosaminoglycans in diabetic nephropathy. Acta Diabetol 1992; 29: 149-155
9. Gambaro G, Venturini AP, Noonan DM et al. Treatment with a glycosaminoglycan formulation ameliorates experimental diabetic nephropathy. Kidney Int 1994; 46: 797-806
10. Tamsma JT, Van den Born J, Bruijn JA et al. Expression of glomerular extracellular matrix components in human diabetic nephropathy: decrease of heparan sulphate in the glomerular basement membrane. Diabetologia, 1994; 37: 313-320
11. Solini A, Carraro A, Barzon I, Crepaldi G. Therapy with glycosaminoglycans lowers albumin excretion rate in non-insulin dependent diabetic patients with macroalbuminuria. Diab Nutr Metab 1994; 7: 304-307
12. Myrup B, Hansen PM, Jensen T, et al. Effect of low-dose heparin on urinary albumin excretion in insulin-dependent diabetes mellitus. Lancet 1995; 345: 421-422
13. Tamsma JT, van der Woude FJ, Lemkes HHPJ. Effect of sulphated glycosaminoglycans on albuminuria in patients with overt diabetic (type 1) nephropathy. Nephrol Dial Transplant 1996; 11: 182-185
14. Velussi M, Cernigoi AM, Dapas F, De Monte A. Glycosaminoglycans oral therapy reduces microalbuminuria, blood fibrinogen levels and limb arteriopathy clinical signs in patients with non-insulin dependent diabetes mellitus. Diab Nutr Metab 1996; 9: 53-58
15. Gambaro G, Baggio B. Glycosaminoglycans: a new paradigm in the prevention of proteinuria and progression of glomerular disease. Nephrol Dial Transplant 1996; 11: 762-764
16. Purkerson ML, Joist JH, Greenberg JM., Kay D, Hoffsten PE, Klahr S. Inhibition by anticoagulant drugs of the progressive hypertension and uremia associated with renal infarction in rats. Thromb Res 1982; 26: 227-240
17. Striker LJ, Peten EP, Elliot SJ, Doi T, Striker GE. Mesangial cell turnover. Effect of heparin and peptide growth factors. Lab Invest 1991; 64: 446-456
18. Castellot JJ, Hoover RL, Harper PA, Karnovsky MJ. Heparin and glomerular epithelial cell-secreted heparin-like species inhibit mesangial-cell proliferation. Am J Pathol 1985; 120: 427-435
19. Deckert T, Feldt-Rasmussen B, Djurup R, Deckert M. Glomerular size and charge selectivity in insulin-dependent diabetes mellitus. Kidney Int 1988; 33: 100-106
20. Kanwar YS, Liu ZZ, Kashihara N, Wallner EI. Current status of the structural and functional basis of glomerular filtration and proteinuria. Semin Nephrol 1991; 11: 390-413
21. Condorelli M, Chiariello M, Dagianti A et al. IPO-V2: a prospective, multicenter, randomized, comparative clinical investigation of the effects of sulodexide in preventing cardiovascular accidents in the first year after acute myocardial infarction. J Am Coll Cardiol 1994; 23: 27-34
22. Deckert T, Feldt-Rasmussen B, Borch-Johnsen K, Jensen T, Kofoed-Enevoldsen A. Albuminuria reflects widespread vascular damage. The Steno hypothesis. Diabetologia 1989; 32: 219-226
23. Van den Born J, van den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assmann KJM, Berden JHM. A monoclonal antibody against GBM heparan sulphate induces an acute selective proteinuria in rats. Kidney Int 1992; 41: 115-123
24. Van den Born J, van den Heuvel LPWJ, Bakker MAH, Veerkamp JH, Assmann KJM, Berden JHM. Distribution of GBM heparan sulphate proteoglycan core protein and side chains in human glomerular diseases. Kidney Int 1993; 43: 454-463
25. Van den Born J, Berden JHM. Is microalbuminuria in diabetes due to changes in glomerular heparan sulphate? Nephrol Dial Transplant 1995; 10: 1277-1296
26. Kanwar YS, Rosenzweig LJ, Linker A, Jakubowski ML. Decreased de novo synthesis of glomerular proteoglycans in diabetes: biochemical and autoradiographic evidence. Proc Natl Acad Sci USA 1983; 80: 2272-2277
27. Colette C, Etienne P, Percheron C et al. Glycosaminoglycan excretion in diabetes mellitus: relation with atherosclerosis and glomerulosclerosis. Diab Nutr Metab 1994; 7: 295-303
28. Crepaldi G, Fellin R, Calabrò A et al. Double-blind multicenter trial on a new medium molecular weight glycosaminoglycan. Current therapeutic effects and perspectives for clinical use. Atherosoclerosis 1990; 81: 233-243
29. Gaddi A, Galetti C, Illuminati B, Nascetti S. Meta-analysis of some results of clinical trials on sulodexide therapy in peripheral occlusive arterial disease. J Int Med Res 1996; 24: 389-406